ReviewFrontiers in immunology2026
Lactylation: a novel epigenetic bridge connecting metabolic reprogramming and immune dysregulation in sepsis-associated ARDS.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute respiratory distress syndrome (ARDS) is driven by metabolic reprogramming and immune dysregulation, but the molecular link between them remains unclear. Lactylation, a lactate-derived post-translational modification, couples metabolic state to transcriptional and functional outcomes in immune and parenchymal cells as an epigenetic reader of glycolytic flux. Recent evidence demonstrates that lactylation regulates macrophage polarization, neutrophil extracellular trap formation, myeloid derived suppressor cell function, and T cell differentiation, while also controlling ferroptosis, autophagy, and endothelial injury in the septic lung. Clinical studies have identified histone H3K18 lactylation as a potential biomarker for sepsis severity and prognosis. This review establishes lactylation as a novel epigenetic bridge connecting metabolic reprogramming and immune dysregulation in sepsis associated ARDS and highlights therapeutic opportunities targeting this modification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.